Connect your agent to akta.pro and build company lists like this across sectors and geos.
Private US-headquartered AI drug discovery companies at Series B or later, ranked by total capital raised. The shortlist includes molecular design, target discovery, protein engineering, biologics, computational chemistry, and AI-enabled therapeutics. Data compiled .
| Company | Category | Most Recent Round | Total Funding | Offering | Management | Revenue Model |
|---|---|---|---|---|---|---|
| NewLimit 🇺🇸 South San Francisco | Epigenetic Therapeutics | Series C Jun 2026 | Funding $682.2M | AI-driven epigenetic reprogramming medicines (Discovery Engine: Ambrosia AI + RESTORE-seq) to restore youthful function in old cells; liver, immune, vascular programs. | Jacob Kimmel Co-founder & CEO Brian Armstrong Co-founder & Board Director Blake Byers Co-founder Melissa Calton Head of Translation | Licensing Royalties |
| Insitro 🇺🇸 South San Francisco | AI-driven drug discovery | Series C Mar 2021 | Funding $643M | Full-stack modality-agnostic AI/ML platform (ML + human genetics + high-throughput biology) for target ID and therapeutic design across small molecules, oligonucleotides, biologics. | Daphne Koller CEO and Founder Philip Tagari Chief Scientific Officer Mary Rozenman CFO and Chief Business Officer Ajamete Kaykas CTO | Licensing Royalties Subscription Recurring |
| Chai Discovery 🇺🇸 San Francisco | AI Drug Discovery | Series C Jul 2026 | Funding $631M | Generative AI foundation models (Chai-1/2/3) predicting and designing biomolecular structures (antibodies, nanobodies, miniproteins) for pharma partners. | Joshua Meier Co-founder and CEO Jack Dent Co-founder and President Matt McPartlon Co-founder Jacques Boitreaud Co-founder | Licensing Royalties Subscription Recurring Professional Services |
| LifeMine Therapeutics 🇺🇸 Watertown | Drug Discovery & Development | Series E Aug 2026 | Funding $563M | Avatar-Rx platform mines fungal genomes via AI/ML, bioinformatics, synthetic biology (Top-Down Drug Discovery) for genetically encoded small molecules (GEMs); lead LIFE-001 in Phase 1. | Gregory Verdine Co-Founder, President and CEO Richard Klausner Co-Founder and Chairman WeiQing Zhou Co-Founder and COO Simon Cooper CMO | One Time License Licensing Royalties |
| Enveda Biosciences 🇺🇸 Boulder | Drug Discovery & Development (Natural Product-Derived Pharmaceuticals) | Series D Sep 2025 | Funding $529.9M | AI-driven natural-product drug discovery combining mass spectrometry with proprietary foundation model (PRISM) and world's largest plant-derived molecule library. | Viswa Colluru Founder & CEO August Allen CTO Hannah Gordon Chief Scientific Officer Jason Kim CFO | Licensing Royalties Subscription Recurring Transaction Fee |
| Valo Health 🇺🇸 Boston | AI Drug Discovery Platform | Series C Oct 2022 | Funding $460M | Opal Computational Platform: integrated cloud-based causal-AI drug discovery/development engine spanning cardiometabolic, oncology, neurodegenerative disease. | Brian M. Alexander CEO Chris Anagnostopoulos Chief Causal AI Officer Karin Conde-Knape Chief Scientific Officer Rita Kale CFO | Licensing Royalties Subscription Recurring |
| Iambic 🇺🇸 San Diego | AI-driven drug discovery platform | Series B Apr 2024 | Funding $396.7M | Enchant transformer models + NeuralPLexer structure prediction integrated with automated wet lab for small-molecule oncology discovery; partners Takeda, Bayer, Jazz. | Tom Miller Co-Founder and CEO Fred Manby Co-Founder and CTO Michael Secora Chief Corporate Development Officer and CFO Neil Josephson CMO | Licensing Royalties |
| Dewpoint Therapeutics 🇺🇸 Boston | Biopharmaceuticals | Series D Sep 2025 | Funding $367.6M | AI-powered ERSA platform + high-throughput condensate phenomics to develop condensate-modulating drugs (c-mods) against undruggable targets (MYC, TDP-43). | Ameet Nathwani CEO Isaac Klein Chief Development and Operating Officer Ann Boija Chief Scientific Officer Anthony Hyman Scientific Co-Founder | Licensing Royalties |
| Arbor Biotechnologies 🇺🇸 Cambridge | Gene Editing Therapeutics | Series C Mar 2025 | Funding $304.5M | AI/ML-driven discovery engine mining metagenomics for a proprietary toolbox of next-gen CRISPR gene editors, licensed to 200+ partners; lead ABO-101 in clinic. | Devyn Smith CEO Pam Stetkiewicz COO Ajim Tamboli CFO Feng Zhang Co-founder | Licensing Royalties Subscription Recurring |
| Genesis Molecular AI 🇺🇸 San Mateo | AI Drug Discovery | Series B Aug 2023 | Funding $296.1M | GEMS AI operating system for drug discovery powered by Pearl foundation model (protein-ligand cofolding); multi-target pharma collaborations (Incyte, Gilead) + internal pipeline. | Evan Feinberg CEO and Co-founder Sergey Edunov CTO Will McCarthy COO Shifeng Pan CSO | Transaction Fee Subscription Recurring Licensing Royalties |
| Immunai 🇺🇸 New York | AI-driven single-cell multiomics platform for immune-related drug discovery | Series B Oct 2021 | Funding $295M | AI-driven single-cell multiomics platform (AMICA-OS) mapping the immune system for target discovery, preclinical evaluation, clinical trial optimization for pharma partners. | Noam Solomon CEO Ansuman Satpathy Scientific Founder Danny Wells Scientific Founder Luis Voloch Co-Founder | Subscription Recurring Professional Services |
| Profluent Bio 🇺🇸 Emeryville | AI Protein Design Platform | Series B Nov 2025 | Funding $256M | Frontier protein language models (ProGen3, up to 46B params) trained on 3.4B-sequence protein atlas; AI-designed gene editors (OpenCRISPR-1), antibodies, enzymes. | Ali Madani Co-founder and CEO Hilary Eaton Chief Business Officer Peter Cameron VP of Gene Editing Stephen Nayfach Head of Bioinformatics | Licensing Royalties Subscription Recurring Professional Services One Time License |
| Numerion Labs 🇺🇸 San Francisco | AI Drug Discovery | Series D Mar 2026 | Funding $241.4M | AI superplatform (COSMOS chemistry foundation model + APEX enumerator + EXPO optimization) for small-molecule discovery in immune/inflammatory disease. (Rebrand of Atomwise.) | Pamela Tsuruda VP, Biology | Licensing Royalties |
| Terray Therapeutics 🇺🇸 Monrovia | AI-driven drug discovery | Series B Oct 2024 | Funding $225M | Proprietary hardware + high-throughput chemical experimentation + generative AI trained on 13B+ target-ligand binding database for small-molecule discovery; partners BMS, Gilead, Calico. | Jacob Berlin CEO Eli Berlin Co-Founder & Chief Business and Financial Officer Lisa L. Decker Chief Business Officer | Licensing Royalties |
| HiFiBiO Cambridge 🇺🇸 Cambridge | Clinical-stage biotherapeutics | Series D Jun 2021 | Funding $179.5M | DIS (Drug Intelligence Science) platform combining single-cell tech + AI/ML analytics for immunotherapy antibody discovery in oncology and I&I; partnered with FibroGen, Novartis. | Fred Dom CEO Jinping Gan Senior VP, Head of R&D Timothy Miller Executive Director, Head of Business Development | Licensing Royalties Subscription Recurring |
| Aureka Biotechnologies 🇺🇸 Laguna Hills | AI-driven antibody therapeutics discovery | Series B Aug 2026 | Funding $168.4M | AuraIDE platform: high-throughput synthetic biology + single-cell microfluidic screening + generative AI (geometric protein LM + RL) for bispecific antibody discovery. | Weian Zhao Founder and CEO Alon Wellner VP of Biology and Co-Founder | Professional Services Licensing Royalties |
| Alloy Therapeutics 🇺🇸 Waltham | Drug Discovery Services | Series E Apr 2026 | Funding $168.2M | Multi-modality biotech ecosystem (ATX-Gx transgenic mice, Keyway TCRm, AntiClastic ASO, iCAR-T) with AI/ML-enabled antibody optimization; 200+ partners, 82VS venture studio. | Errik Anderson Founder, CEO, Chairman Piotr Bobrowicz President Mike Schmidt CSO | Licensing Royalties |
| Verge Genomics 🇺🇸 San Francisco | AI Drug Discovery Platform | Series C Oct 2024 | Funding $134.1M | AI foundation models (vBx, Converge) trained on 12,000+ profiled brains for neuroscience target discovery, biomarkers, patient stratification; pivoted to data-services model after Phase 1 failure. | Alice Zhang Co-Founder & CEO Jason Chen Co-Founder Diego Cadavid CMO | Data Monetisation Subscription Recurring |
| QuantX Biosciences 🇺🇸 Princeton | Computational Drug Discovery | Series B Feb 2026 | Funding $130M | Computational platform (molecular dynamics + deep learning + FEP/QM simulation) designing oral small-molecule inhibitors against validated immunology/inflammation and oncology targets. | Wei Li Interim CEO and Director Wayne Tang Co-founder and President Yax Sun Co-founder and CTO | Licensing Royalties Professional Services |
| Moonwalk Biosciences 🇺🇸 South San Francisco | Epigenetic Therapeutics — Cardiometabolic Drug Discovery | Series B Sep 2026 | Funding $127M | EpiRead methylome-mapping + EpiWrite epigenetic-editing platforms with AI-driven adipose-biology discovery engine (Methylencoder) for obesity/cardiometabolic disease; pivoting toward siRNA. | Alex Aravanis Co-Founder, CEO | Licensing Royalties |
| Cartography Biosciences 🇺🇸 South San Francisco | Oncology Therapeutics | Series B Oct 2025 | Funding $124M | ATLAS single-cell antigen atlas + SUMMIT multi-specificity AI/ML platform identifying tumor-selective antigens for antibody-based cancer immunotherapies; deals with Pfizer, Gilead. | Kevin Parker Co-founder and CEO Dan Rock Chief Scientific Officer Dirk Nagorsen CMO | Licensing Royalties Transaction Fee |
| Peptilogics 🇺🇸 Pittsburgh | Peptide Therapeutics | Series B Oct 2025 | Funding $122.1M | Nautilus AI computational peptide design platform with purpose-built supercomputing; lead PLG0206 (zaloganan) in pivotal Phase 2/3 for prosthetic joint infections. | Jonathan Steckbeck Co-founder, President and CEO Nicholas Nystrom CTO | One Time License |
| Octant Bio 🇺🇸 Los Angeles / Emeryville | Drug Discovery Platform / Biopharmaceuticals | Series B Apr 2022 | Funding $115M | Octant Navigator: Generative Biology (RNA-barcoded cell sensors) + Generative Chemistry + Generative AI in weekly DBTL cycle targeting protein misfolding diseases; lead OCT-980 in Phase 1. | Sri Kosuri Co-founder & CEO Ramsey Homsany Co-founder & President Dean Rick Artis CSO | Licensing Royalties Subscription Recurring Managed Services |
| Unnatural Products 🇺🇸 Santa Cruz | Biopharmaceutical Drug Discovery | Series B Mar 2026 | Funding $83M | AI/ML-enhanced macrocyclic peptide drug discovery platform (in silico tools + direct-to-biology chemistry) engineering orally bioavailable peptides against undruggable targets; deals with Novartis, argenx, Merck. | Cameron Pye Co-Founder & CEO Joshua Schwochert Co-Founder & CSO | Licensing Royalties Subscription Recurring |
| Prellis Biologics 🇺🇸 Berkeley | Therapeutic Antibody Discovery & Development | Series C May 2026 | Funding $79.37M | EXIS platform: 3D bioprinted human lymph-node organoids + AI/ML (AntiGen AI) for rapid fully-human antibody discovery; partners Eli Lilly, Sanofi, BMS. | Michael Nohaile CEO Melanie Matheu Founder and CTO Les Miranda CSO | Licensing Royalties |
| Aitia 🇺🇸 Somerville / Cambridge | Drug Discovery Software | Series D Jul 2019 | Funding $77.26M | Gemini Digital Twins platform: Causal AI (REFS engine) building in silico causal models of disease biology from multiomics/clinical data to identify novel drug targets for biopharma partners. | Colin Hill CEO Bruce Church Chief Mathematics Officer | Subscription Recurring |
| Envisagenics 🇺🇸 Long Island City | AI-driven RNA splicing drug discovery platform | Series B Jun 2024 | Funding $52.06M | SpliceCore AI/ML platform decoding RNA splicing to identify therapeutic targets in oncology/neurodegeneration; SpliceIO module for immuno-oncology; partners BMS, Biogen, J&J. | Maria Luisa Pineda CEO & Co-founder Martin Akerman CTO & Co-founder | Professional Services Subscription Recurring Licensing Royalties |
| Cyrus Biotechnology 🇺🇸 Seattle | Computational Protein Design Platform | Series B Feb 2024 | Funding $46.84M | Rosetta-based computational protein design + proprietary AI + deep mutagenesis scanning to re-engineer biologics for 120+ pharma partners; internal pipeline led by IdeS candidate CYR212. | Lucas Nivon Co-founder & CEO Erik Procko CSO & Director of Discovery David Baker Scientific Co-Founder & Advisor (2024 Nobel Laureate) | Licensing Royalties Professional Services |
| Cellworks 🇺🇸 South San Francisco | Computational Precision Medicine / Oncology Decision Support | Series B Dec 2012 | Funding $33M | Mechanistic AI computational biosimulation (Computational Biology Model) predicting personalized cancer therapy response; clinical decision support (Singula TRI) plus pharma drug-repurposing services. | Yatin Mundkur CEO Shireen Vali Co-founder & CSO | Subscription Recurring Professional Services |
| Pattern Computer 🇺🇸 Friday Harbor / Redmond | AI-Powered Pattern Discovery Platform | Series B Feb 2022 | Funding $26.13M | Domain-agnostic explainable-AI platform (Pattern Discovery Engine) applied across oncology drug discovery, hyperspectral diagnostics, finance, physics; lead oncology asset PCI020302. | Mark R. Anderson Chair and CEO Ty Carlson CTO | Licensing Royalties Subscription Recurring Hardware Sales |
AI drug discovery companies apply machine learning to therapeutic discovery and development, from target identification through molecular, protein, and antibody design. Of the 30 companies here, 8 describe themselves generically as AI(-driven) drug discovery platforms, while the rest specialize in areas such as protein and antibody design, epigenetic and gene-editing therapeutics, and computational chemistry or multiomics platforms, each represented by 1 company.
The distinction that matters most is against conventional computational-chemistry vendors that sell only software tools. On this list, 25 of the 30 companies monetize partly through licensing and royalty arrangements with pharmaceutical partners, tying revenue to the drug programs their platforms help advance rather than to software seats alone.
Series B is the most common funding stage, reached by 16 of the 30 companies. The San Francisco Bay Area anchors the sector, home to 8 of the 30 companies (5 in South San Francisco, 3 in San Francisco), with Boston and Cambridge, Massachusetts together home to 4 more.
Universe: US-headquartered, currently operating private companies with Series B or higher funding and an AI maturity rating of 3 or above, matched against akta.pro industry codes for AI/ML drug discovery and AI/ML-enabled biologic discovery platforms.
Companies are tagged against standard industry codes and against akta.pro's internal taxonomy, so the same set can be rebuilt by code, by segment, or by a combination of both.
NAICS 541714 Research and Development in Biotechnology (except Nanobiotechnology) 325414 Biological Product (except Diagnostic) Manufacturing 511210 Software Publishers SIC 8731 Commercial Physical and Biological Research 2836 Biological Products, Except Diagnostic Substances 7372 Prepackaged Software Internal taxonomy HLAGAJAO AI/ML Platforms for Drug Discovery & Experiment Optimization HLAAAIAE AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) HLAAAIAB Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) HLAAAIAH Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) HLAAAIAL Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)Industry codes are provided for cross-referencing against public filings and procurement records. akta.pro classification is independent of them, so a company may carry an internal segment without a matching NAICS or SIC registration.